AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value

$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie adjusted R&D Expense — Non-GAAP ($M) ($M)

Form 8-K Non-GAAP Reconciliations

Quarterly Annual

Latest, FY2025

Period ended Dec 31, 2025

Change on a year earlier

-99.8%

8,056 in FY2024

History

4 years

Since FY2022

Sources

Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Adjusted R&D Expense — Non-GAAP ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	18	-99.8%	Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
FY2024	Dec 31, 2024	8,056	+14.6%	Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
FY2023	Dec 31, 2023	7,029	+9.2%	Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
FY2022	Dec 31, 2022	6,435	–	Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗

Cite this data

StockData. (2026). AbbVie Adjusted R&D Expense — Non-GAAP ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd_adj_exp

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.